New drug aims to tame cortisol overload from adrenal tumors

NCT ID NCT04308590

Completed Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tested a drug called relacorilant in 137 people with hypercortisolism caused by adrenal adenomas or hyperplasia. The goal was to see if it could improve blood sugar control and lower high blood pressure. Participants received either relacorilant or a placebo for a set period, and researchers measured changes in blood pressure and glucose levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: relacorilant
What this could lead to: If successful, relacorilant could offer a new treatment option to control blood sugar and blood pressure in people with hypercortisolism.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The drug may not prove effective or could have side effects. It is not a cure and requires ongoing management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cortisol-producing adrenal cortex adenoma Cushing syndrome Cushing syndrome due to macronodular adrenal hyperplasia ectopic ACTH secretion syndrome hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCORTISOLISM

Contacts and locations

Locations

Site 01

Wilmington, North Carolina, 28401, United States
Site 02

Summerville, South Carolina, 29485, United States
Site 03

El Paso, Texas, 79935, United States
Site 05

Fort Worth, Texas, 76132, United States
Site 06

Jackson, Mississippi, 39202, United States
Site 07

Atlanta, Georgia, 30318, United States
Site 08

Houston, Texas, 77079, United States
Site 09

Metairie, Louisiana, 70006, United States
Site 10

Jamaica, New York, 11432, United States
Site 11

Fall River, Massachusetts, 02721, United States
Site 13

Seville, 41013, Spain
Site 14

Málaga, 29006, Spain
Site 15

Spokane, Washington, 99202, United States
Site 16

Indianapolis, Indiana, 46202, United States
Site 17

Stanford, California, 94305, United States
Site 20

Dallas, Texas, 75390, United States
Site 21

Columbus, Ohio, 43201-3209, United States
Site 22

Sofia, 01431, Bulgaria
Site 23

Tel Aviv, Israel
Site 25

Vienna, State of Vienna, 1090, Austria
Site 26

Valencia, 46026, Spain
Site 27

Birmingham, Alabama, 35294, United States
Site 28

Naples, 80131, Italy
Site 30

Cleveland, Ohio, 44195, United States
Site 31

Rome, Roma, 00189, Italy
Site 32

Ramat Gan, 5265601, Israel
Site 33

Rochester, Minnesota, 55905, United States
Site 34

Milan, Italy
Site 35

Lublin, Poland
Site 36

Baltimore, Maryland, 21287, United States
Site 37

Rome, 00161, Italy
Site 38

Bucharest, 011863, Romania
Site 40

Milan, Milano, 20122, Italy
Site 41

Bucharest, 011863, Romania
Site 42

Bucharest, 010825, Romania
Site 43

Orbassano, Torino, Italy
Site 44

New York, New York, 10021, United States
Site 46

Würzburg, 97080, Germany
Site 47

Krakow, 31-501, Poland
Site 48

Gliwice, 44-102, Poland
Site 50

Munich, Bavaria, 80336, Germany
Site 51

Padova, 35128, Italy
Site 52

Torino, 10126, Italy
Site 53

Torrance, California, 90502, United States
Site 54

Reno, Nevada, 89511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.